With the waning COVID caseload in active site loca
Post# of 153822
(Total Views: 461)
Posted On: 05/28/2020 12:03:57 PM
With the waning COVID caseload in active site locations (except UCLA), I'm taking a stab at listing the pros and cons of peeking at the phase 2 trial data. I'm focusing on Mild/Mod since Severe is an obvious choice at 50.
Pros:
-If positive results, can be submitted to FDA for early consideration
-If positive results, could generate publicity to accelerate trial completion and investment
Cons
-if underwhelming results and nothing announced, critics will suspect the worst.
-if submitted to FDA, they could reject and/or negatively alter trial requirements going forward?
Did I miss or misrepresent anything? Also, if CYDY takes a peek, must it be publicly disclosed? I'm just trying to anticipate how the CYDY board of directors will approach this.
Pros:
-If positive results, can be submitted to FDA for early consideration
-If positive results, could generate publicity to accelerate trial completion and investment
Cons
-if underwhelming results and nothing announced, critics will suspect the worst.
-if submitted to FDA, they could reject and/or negatively alter trial requirements going forward?
Did I miss or misrepresent anything? Also, if CYDY takes a peek, must it be publicly disclosed? I'm just trying to anticipate how the CYDY board of directors will approach this.
(0)
(0)